Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

While both drugs belong to the GLP-1 receptor agonist class, Mounjaro has a dual mechanism (GIP and GLP-1), which clinical ...

By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss ...

India's obesity drug market is set for intense competition with Novo Nordisk launching Wegovy to challenge Eli Lilly's Mounjaro, which gained early traction. Both drugs address rising obesity and ...

Danish drugmaker Novo Nordisk has launched its popular weight-loss drug Wegovy in India, months after its rival Mounjaro’s ...

Danish pharma giant Novo Nordisk’s announcement comes months after launch of another top selling obesity drug Mounjaro in ...

We wanted to price it in India in a way which is comparable to the therapies that are available,' said Vikrant Shrotriya, ...

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

Novo Nordisk (NVO) has launched its blockbuster weight-loss drug Wegovy in India, shortly after rival Eli Lilly (NYSE:LLY) introduced its popular weight loss/diabetes therapy Mounjaro in the country ...

The Danish company has introduced five dosage options for its self-injectable weight-loss drug, with variable monthly pricing for the higher strengths.